International Journal of Clinical Cardiology最新文献

{"title":"Transcatheter Tricuspid Valve Replacement and Repair: Pooled Analysis of the Outcomes and Complications of Novel Emerging Treatments","authors":"Khalid Yaser, Dasu Neethi, Dasu Kirti","doi":"10.23937/2378-2951/1410179","DOIUrl":"https://doi.org/10.23937/2378-2951/1410179","url":null,"abstract":"Background: Tricuspid regurgitation is a poor prognostic marker of end-stage heart failure. Treatment options for severe tricuspid regurgitation are currently limited because these procedures have the highest mortality rates of all valve procedures. Isolated tricuspid valve surgery is reserved for rare cases during surgical viability evaluation with repair favored over tricuspid valve replacement, owing to the slightly more favorable mortality and downstream complication associated with the latter. Transcatheter tricuspid valve repair or replacement (collectively, TVTT), on the other hand, are extremely promising interventions due to the minimally invasive nature of these treatments. Multiple devices are currently being developed and tested for TTVT to offer surgeons a safer alternative than the aforementioned traditionally high-risk surgical procedures. Objective: The aim of this study is to examine the complications of these procedures from day 0 of procedure to up to 1 year of follow up. Methods: Six studies were included, 3 were registries (TriVALVE, TRILUMINATE, TRAMI), surveying a total of 336 patients. Complications following the procedures were pooled and analyzed. Results: From procedure to up to 1 year, there was 14.3% mortality (49/342), 0.3% incidence of myocardial infarction and TIA/stroke (1/342), 2% device embolization and/ or leaflet detachment (7/342), 5.2% major/minor bleeding (18/342), 0.9% AKI (3/342), 1.1% infections and arrhythmias (4/342). Conclusions: Despite a narrow sample size due to the novelty of these procedures and varying lengths of follow-up (30 days to 1 year), transcatheter tricuspid valve repair and replacement prove to be promising interventions. Mortality was significant at 14.6%, but patients with severe tricuspid regurgitation have a poor prognosis overall without intervention along with higher comparative mortality rates. Research aimed at further investigating TVTT procedures and prospective clinical trials to establish these treatments as mainstays for severe tricuspid regurgitation is necessary.","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115287786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Misleading Diagnosis: Anterolateral STEMI Disguising Type A Aortic Dissection in Postpartum","authors":"B. Hema, W. Thomas","doi":"10.23937/2378-2951/1410177","DOIUrl":"https://doi.org/10.23937/2378-2951/1410177","url":null,"abstract":"• Page 1 of 4 • Balina and Wool. Int J Clin Cardiol 2020, 7:177 Citation: Balina H, Wool T (2020) A Misleading Diagnosis: Anterolateral STEMI Disguising Type A Aortic Dissection in Postpartum. Int J Clin Cardiol 7:177. doi.org/10.23937/2378-2951/1410177 Accepted: May 30, 2020; Published: June 01, 2020 Copyright: © 2020 Balina H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. In the lab she was found to be increasingly hypoxemic and had an episode of vomiting, requiring intubation. Transthoracic echocardiogram showed mild moderate left ventricular dysfunction with no pericardial effusion. The right femoral artery and vein were accessed percutaneously. A 6 French JR4 catheter over a J wire was advanced into the ascending aorta, however due to difficulty encountered in passing the catheter through aortic valve, there was a suspicion for aortic dissection and injection through Judkins catheter confirmed the presumed diagnosis (Figure 2).","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130798743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Left Ventricular Pseudo-Aneurysm","authors":"H. Allam, Hayder Ousama","doi":"10.23937/2378-2951/1410178","DOIUrl":"https://doi.org/10.23937/2378-2951/1410178","url":null,"abstract":"• Page 1 of 3 • Harfoush and Hayder. Int J Clin Cardiol 2020, 7:178 Citation: Harfoush A, Hayder O (2020) A Case of Left Ventricular Pseudo-Aneurysm. Int J Clin Cardiol 7:178. doi.org/10.23937/2378-2951/1410178 Accepted: May 30, 2020; Published: June 01, 2020 Copyright: © 2020 Harfoush A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Medication history","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127680420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality over Quantity: A Case Based Review of HDL Function and Dysfunction","authors":"S. Suleiman, J. Coughlan, M. Vincent","doi":"10.23937/2378-2951/1410176","DOIUrl":"https://doi.org/10.23937/2378-2951/1410176","url":null,"abstract":"• Page 1 of 7 • Suleiman et al. Int J Clin Cardiol 2020, 7:176 Citation: Suleiman S, Coughlan JJ, Maher V (2020) Quality over Quantity: A Case Based Review of HDL Function and Dysfunction. Int J Clin Cardiol 7:176. doi.org/10.23937/2378-2951/1410176 Accepted: May 14, 2020; Published: May 16, 2020 Copyright: © 2020 Suleiman S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. A large number of proteins involved in inflammation, complement regulation, and innate immunity are physiologically bound to HDL [5]. These reinforce the concept that HDL evolved as a component of the innate immune system and is reflected in its pleiotropic functions in the body [6]. With its constant remodeling via enzymes and tissues, various subclasses, structural diversity, interactions, and functionality, HDL has a larger role in health and disease [7]. This inverse correlation between raised levels of HDL and ASCVD is not necessarily causal [8] and numerous studies have failed to show reduced ASCVD risk with elevation of HDL [9-11]. Contemporary data has highlighted that higher levels of HDL may be detrimental to cardio-vascular health, demonstrating a unique U-shape association between raised HDL and ASCVD risk [12] in men. This paradoxical rise in ASCVD risk is likely driven by several reasons including genetic mutation, the concept of HDL dysfunction and inflammation. This had led to an increasing interest in quantifying HDL function and though the reverse cholesterol transport process (RCT) has been given primacy with regard to the proposed mechanistic relationship between HDL and ASCVD, HDL also demonstrates anti-inflammatory, anti-apoptotic, anti-oxidative and vaso-protective properties [13-16].","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124557813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Spontaneous Coronary Artery Dissection Leading to Recurrent Sudden Cardiac Arrests: Who is at Risk?","authors":"Weber Anthony, Elliott Joseph, Gopalakrishnan Prabhakaran","doi":"10.22541/au.158879390.06221983","DOIUrl":"https://doi.org/10.22541/au.158879390.06221983","url":null,"abstract":"Spontaneous coronary artery dissection(SCAD) is a rare cause of acute coronary syndrome(ACS) with medical management and conservative therapies usually resulting in favorable outcomes. SCAD often is recurrent, especially in high risk individuals with underlying connective tissue disorders. Lethal ventricular arrhythmias have been reported in SCAD without clear indications for secondary prevention with implantable cardiovert-defibrillator(ICD). Depending on risk factor for recurrence as well as susceptibility towards ventricular arrhythmias some patients may benefit from early implantations of ICDs. *Correspondence to: Anthony G Weber, Department of Medical Education, Aultman Hospital, 2600 6th St. SW Canton, Ohio 4479, USA, Tel: 3309332629, E-mail: Anthony.Weber@aultman.com","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134352571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Bromocriptine for the Treatment of Peripartum Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials","authors":"E. VillanuevaDanielleLouis, Evangelista Lauren Kay, Espanillo-Villanueva Ma Cristina, C. AnonuevoJohn","doi":"10.23937/2378-2951/1410171","DOIUrl":"https://doi.org/10.23937/2378-2951/1410171","url":null,"abstract":"Background Peripartum cardiomyopathy is a rare, pregnancy associated cause of left ventricular heart failure in previously healthy women. It remains an important cause of cardiac-related maternal morbidity and mortality worldwide. Half of the patients will recover left ventricular function after 6 months. However, in the remainder of patients who do not recover cardiac function, they will require advanced heart failure therapies. Bromocriptine, a dopamine agonist which inhibits prolactin release, has demonstrated improvement in left ventricular recovery and clinical outcome. We sought to determine the effect of adding Bromocriptine to standard heart failure therapy on the improvement and recovery of left ventricular function and cardiovascular mortality of these patients. Inclusion Criteria. Studies were included if they satisfied the following criteria:1) Randomized Controlled Trials; 2) Pregnant patients who fulfilled the criteria for diagnosis of peripartum cardiomyopathy and 3) Reported data on improvement in left ventricular ejection fraction and clinical outcomes. Methods. Using PUBMED, Clinical Key, Science Direct, Scopus, and Cochrane databases, a search for eligible studies was conducted from June to December 31, 2018. The quality of each study was evaluated using the Cochrane Risk of Bias Tool. The primary outcome of interest is on the effect of Bromocriptine on the improvement of left ventricular function and clinical outcomes among these patients. Review Manager 5.3 was utilized to perform analysis of random effects for continuous outcomes. Results. We identified 2 randomized controlled trials of 116 pregnant patients diagnosed with peripartum cardiomyopathy, showing that among those who received Bromocriptine on top of standard heart failure therapy, there is a significant improvement in the left ventricular ejection fraction at 6 months [mean difference 15.14 (95% CI, 6.53 to 23.75) p <0.05] compared to standard heart failure therapy alone. It was also observed that those who received Bromocriptine had better clinical outcomes. Conclusion. The addition of Bromocriptine on top of standard heart failure therapy significantly improved the left ventricular ejection fraction of patients with peripartum cardiomyopathy at 6-months post-partum. This novel therapy may be considered to improve the management of these patients.","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130545464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Hemopericardium as an Adverse Effect of Rivaroxaban Administration","authors":"Surani Asif, Quintero Beatriz Martinez, Brual David, Elias Hadi, Ahmed Fahad Uddin, Peterson Matthew","doi":"10.23937/2378-2951/1410161","DOIUrl":"https://doi.org/10.23937/2378-2951/1410161","url":null,"abstract":"Rivaroxaban is a direct oral anticoagulant with a favorable safety profile when compared to warfarin in respect to bleeding. During post-marketing surveillance, intracranial and retroperitoneal bleedings have been reported; however, hemopericardium has not been frequently described. In this case series, we present three cases of spontaneous hemopericardium where rivaroxaban was thought to be the causative agent. Predisposing factors for rivaroxaban induced hemopericardium might include impaired kidney function, concomitant use of antiplatelet agents, herbal supplements, and CYP3A4 metabolizers and inhibitors. Clinicians should be aware of the possibility of such life-threatening adverse event in patients taking rivaroxaban and should consider it in their differential diagnosis in a patient presenting with chest pain and/or dyspnea while on rivaroxaban. This case series suggests that rivaroxaban induced hemopericardium might not be as rare as initially thought. CAsE REPoRt","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"132 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128598604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Hydrochlorothiazide in the Real World: A Commentary on the Italian Medicines Agency (AIFA) Pronouncements","authors":"Magro Valerio Massimo, Coppola Carla, Boccalone Eugenio, Caturano Michele, Scala Giovanni, Verrusio Walter","doi":"10.23937/2378-2951/1410160","DOIUrl":"https://doi.org/10.23937/2378-2951/1410160","url":null,"abstract":"• Page 1 of 3 • Magro et al. Int J Clin Cardiol 2019, 6:160 Citation: Magro VM, Coppola C, Boccalone E, Caturano M, Scala G, et al. (2019) Safety of Hydrochlorothiazide in the Real World: A Commentary on the Italian Medicines Agency (AIFA) Pronouncements. Int J Clin Cardiol 6:160. doi.org/10.23937/2378-2951/1410160 Accepted: October 12, 2019; Published: October 14, 2019 Copyright: © 2019 Magro VM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. volume, hyponatremia, hypercalcemia, hyperglycemia, dyslipidemia) [9]. Regarding the electrolyte imbalances, thiazide-induced hyponatremia is certainly an important medical condition, that is regularly present in the internal medicine departments and it causes substantial morbidity to frail patients, often elderly, who are taking hydrochlorothiazide, in subgroups of patients [10,11]. Equally not yet well understood is the mechanism by which hydrochlorothiazide interferes with the glucose homeostasis [12-14]. There is also a whole range of side effects, fortunately rarer, but described in the medical literature, ranging from the appearance of lupus [15], interstitial lung disease [16], even severe allergic states [17], pulmonary edema [18-20], all conditions linked to immunological changes induced by the molecule itself. The effect on the sense organs (hypoacusis) is more known and less rare (although investigated with low frequency, especially in the elderly subjects), with various reports from the organs of vigilance drug, for which there are well defined indications for the diagnosis of this adverse event (Austin Bradford-Hill criteria, Naranjo criteria), well applied in pharmacovigilance [21,22].","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133037767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Platelet/Lymphocyte Ratio and Angiographic No-Reflow in Patients with None-St Segment Elevation Acute Myocardial Infarction Undergoing Primary Coronary Intervention","authors":"Asoğlu Ramazan, Afşin Abdulmecit, Asoğlu Emin, S. Arif","doi":"10.23937/2378-2951/1410159","DOIUrl":"https://doi.org/10.23937/2378-2951/1410159","url":null,"abstract":"Introduction: Inflammation and platelet activation play a central role in the initiation and progression of the atherosclerosis process. The Platelet-to-lymphocyte ratio (PLR) is a new prognostic marker in coronary artery disease. The PLR is a significant independent predictor of longterm mortality after none-ST elevated myocardial infarction (NSTEMI). We aimed to evaluate the relationship between PLR and no-reflow (NR) in patients with NSTEMI. Material and methods: The present study included 173 patients with NSTEMI. The patients were classified into two groups as follows: 115 patients in the NR group and 58 patients in the normal reflow group. NR was defined as coronary thrombolysis in myocardial infarction (TIMI) flow grade ≤ 2 after vessel recanalization with primary percutaneous coronary intervention. The PLR was calculated from the complete blood count. Results: The PLR values of the patients with NR were significantly higher than those of patients with normal reflow (108.6 (14.6-511.3) vs. 91.7 (17.2-225.3), p = 0.01). Also, neutrophil-to-lymphocyte ratio (NLR) was significantly higher in the NR group than the normal-reflow group (3.0 (0.316.5) vs. 2.3 (0.01-12.5), p = 0.02). The Correlation between the PLR and NLR was positive and significant (r = 0.68, p < 0.001). Conclusion: This study showed that PLR is an independent predictor of NR in patients with NSTEMI.","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"107 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114649456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Atherosclerosis Treated by Hybrid Surgical and Systemic Percutaneous Endovascular Management","authors":"Hassan Walid, A. Amr, H. Mariam, Saadi Khaldoun Al, E. Sharaf","doi":"10.23937/2378-2951/1410158","DOIUrl":"https://doi.org/10.23937/2378-2951/1410158","url":null,"abstract":"Atherosclerotic disease in one arterial site, raise the probability of having other sites affected by about 50% within the vascular axis. Hence once vascular pathology found in one site i.e. coronary artery disease (CAD), other sites i.e. Cerebral and peripheral circulation must be assessed thoroughly, especially in patients with multiple risk factors. Percutaneous intervention (PCI) is a conservative reasonable solution for high risk and inoperable cases; sometimes it supersedes the choice surgery especially with the new era of drug eluting stents (DES) and combined Anti-Ischemic medications. Coronary artery bypass graft (CABG) rather than PCI was the favored cost-effective treatment for complex multivessel coronary artery disease (MVCAD) in the long term [1]. While the evidence base for the cost-effectiveness of DES compared with CABG is growing [1]. Despite the benefits of Coronary Artery Bypass Graft surgery, 15% to 25% of patients develop graft closure within one year following the procedure [2]. Carotid atherosclerotic disease can lead to ischemic stroke or transient ischemic attack (TIA) from embolization, thrombosis, or hemodynamic compromise [3]. Carotid endarterectomy (CEA) was the initial and sole revascularization method for a significant > 70% stenosis [3-12], followed later by introduction of transcatheter Percutaneous angioplasty and stenting [13-20]. For a selected patients with carotid stenosis of 70 to 99 percent, carotid artery stent (CAS) rather than carotid endarterectomy (CEA) is recommended if any of the following conditions are present: A carotid lesion that is not suitable for surgical access, Radiation-induced stenosis, restenosis after CEA, and clinically significant cardiac, pulmonary, or other disease that greatly increases the risk of anesthesia and surgery [13-24]. We hereby present a case of 78-years-old with severe coronary, carotid and peripheral arterial atherosclerosis who showed a successful example of the solution of Hybrid approach of surgical and stenting approach in such cases.","PeriodicalId":112011,"journal":{"name":"International Journal of Clinical Cardiology","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133947617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}